Literature DB >> 20216125

Osteonecrosis in patients after severe acute respiratory syndrome (SARS): possible role of anticardiolipin antibodies.

Wei Sun1, Bai-Liang Wang, Bing-Li Liu, Feng-Chao Zhao, Zhen-Cai Shi, Wan-Shou Guo, Zhao-Hui Liu, Zi-Rong Li.   

Abstract

OBJECTIVES: This study examined the anticardiolipin antibodies in post-SARS (severe acute respiratory syndrome) osteonecrosis patients to investigate the etiology of post-SARS osteonecrosis, and to eventually provide valuable information for the early diagnosis of nontraumatic osteonecrosis and for the susceptible population screening.
METHODS: This study recruited 62 post-SARS osteonecrosis patients and 52 age- and gender-matched healthy controls. Fasting blood samples were collected from all the subjects through cubital veins. Immunoglobulins A, G and M (IgA, G and M) types of anticardiolipin antibodies were examined by enzyme-linked immunosorbent assay. The routine examinations of prothrombin time, thrombin time, prothrombin activity, and international normalized ratio were also performed.
RESULTS: There were 21 of 62 post-SARS osteonecrosis patients (33.9%) who showed at least one type of anticardiolipin antibodies. The titers of specific IgA, IgG, and IgM were 11.33 +/- 11.209 APL, 5.127 +/- 5.927 GPL, and 17.821 +/- 10.606 MPL, respectively. There were only 4 of 52 subjects in the control group (7.7%) who showed positive anticardiolipin antibody with titers of IgA at 10.702 +/- 3.126 APL, IgG at 5.184 +/- 4.780 GPL, and IgM at 14.684 +/- 5.516 MPL. There were significant differences between the 2 groups confirmed by t-Test and chi(2) test (P < 0.05), while no significant differences were observed in prothrombin time, thrombin time, prothrombin activity, and international normalized ratio results between the 2 groups.
CONCLUSIONS: The incidences of anticardiolipin antibodies were increased in the post-SARS osteonecrosis patients and anticardiolipin antibodies may play a role in the pathogenesis of post-SARS osteonecrosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20216125     DOI: 10.1097/RHU.0b013e3181cf3464

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  8 in total

Review 1.  Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past.

Authors:  Dimitrios Giannis; Ioannis A Ziogas; Panagiota Gianni
Journal:  J Clin Virol       Date:  2020-04-09       Impact factor: 3.168

2.  Late acute pulmonary embolism after mild Coronavirus Disease 2019 (COVID-19): a case series.

Authors:  Hareton Teixeira Vechi; Lucas Rodrigues Maia; Manoella do Monte Alves
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2020-09-04       Impact factor: 1.846

3.  A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.

Authors:  Angkana T Huang; Bernardo Garcia-Carreras; Matt D T Hitchings; Bingyi Yang; Leah C Katzelnick; Susan M Rattigan; Brooke A Borgert; Carlos A Moreno; Benjamin D Solomon; Luke Trimmer-Smith; Veronique Etienne; Isabel Rodriguez-Barraquer; Justin Lessler; Henrik Salje; Donald S Burke; Amy Wesolowski; Derek A T Cummings
Journal:  Nat Commun       Date:  2020-09-17       Impact factor: 14.919

4.  General recommendation for assessment and management on the risk of glucocorticoid-induced osteonecrosis in patients with COVID-19.

Authors:  Wenlong Li; Zeqing Huang; Biao Tan; Gang Chen; Xugui Li; Kan Xiong; Ruizheng Zhu; Ruihan Li; Shuwen Li; Hengli Ye; Zhi Liang; Xiaojun Dong; Shijing Zhou; Song Chen; Haixiang Xi; Hao Cheng; Rongpeng Xu; Shenghao Tu; Zhe Chen; Lihua Qi; Jiandong Song; Ruoran Xiao; Huilan Liu; Qian Nan; Huiyong Yu; Hongsheng Cui; Yanguang Shen; Chengxiang Wang; Na Lin; Yanqiong Zhang; Weiheng Chen
Journal:  J Orthop Translat       Date:  2021-10-20       Impact factor: 5.191

Review 5.  Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.

Authors:  Jaume Alijotas-Reig; Enrique Esteve-Valverde; Cristina Belizna; Albert Selva-O'Callaghan; Josep Pardos-Gea; Angela Quintana; Arsene Mekinian; Ariadna Anunciacion-Llunell; Francesc Miró-Mur
Journal:  Autoimmun Rev       Date:  2020-05-03       Impact factor: 9.754

Review 6.  Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses.

Authors:  Eleni Gavriilaki; Panagiota Anyfanti; Maria Gavriilaki; Antonios Lazaridis; Stella Douma; Eugenia Gkaliagkousi
Journal:  Curr Hypertens Rep       Date:  2020-08-27       Impact factor: 5.369

7.  Relationship between post-SARS osteonecrosis and PAI-1 4G/5G gene polymorphisms.

Authors:  Wei Sun; Zirong Li; Zhengcai Shi; Bailiang Wang; Fuqiang Gao; Yurun Yang; Wanshou Guo
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-04-16

Review 8.  Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?

Authors:  Jayakanthan Kabeerdoss; Debashish Danda
Journal:  Int J Rheum Dis       Date:  2020-08-10       Impact factor: 2.454

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.